Bionano Genomics reported a 13% year-over-year decline in total revenues for Q2 2025, totaling $6.7 million driven primarily by a 67% drop in service revenues despite a 3% decrease in product sales. The company has increased its optical genome mapping system installed base by seven units and anticipates 20 to 25 new installations for the year. Cost reductions helped lower net losses compared to the prior year quarter, although profitability remains elusive.